Company Description Adimab–which stands for Antibody Discovery Maturation Biomanufacturing–is developing a platform that’s deliberately engineered to minimize and potentially eliminate third party royalties, offering a one-stop-service-shop to a select few Big Pharma partners.
Proceeds Purposes We are accelerating the expansion of our platform to include additional applications such as the development of bi-specific antibodies, antibody-drug conjugates, targeting cell based antigens including GPCRs and ion channels, as well as preclinical manufacturing and mammalian cell line development.